Table 3S. Detailed clinical information for the 163 AML patients from TARGET database																																																																
TARGET USI	Gender	Race	Ethnicity	Age at Diagnosis in Days	First Event	Event Free Survival Time in Days	Vital Status	Overall Survival Time in Days	Year of Diagnosis	Year of Last Follow Up	Protocol	WBC at Diagnosis	Bone marrow leukemic blast percentage (%)	Peripheral blasts (%)	CNS disease	Chloroma	FAB Category	t(6;9)	t(8;21)	t(3;5)(q25;q34)	t(6;11)(q27;q23)	t(9;11)(p22;q23)	t(10;11)(p11.2;q23)	t(11:19)(q23:p13.1)	inv(16)	del5q	del7q	del9q	monosomy 5	monosomy 7	trisomy 8	trisomy 21	MLL	Minus Y	Minus X	Cytogenetic Code Other	Cytogenetic Complexity	Primary Cytogenetic Code	ISCN	FLT3/ITD positive?	FLT3/ITD allelic ratio	FLT3 PM	NPM mutation	CEBPA mutation	WT1 mutation	c-Kit Mutation Exon 8	c-Kit Mutation Exon 17	MRD at end of course 1	MRD % at end of course 1	MRD at end of course 2	MRD % at end of course 2	CR status at end of course 1	CR status at end of course 2	Risk group	SCT in 1st CR	Bone Marrow Site of Relapse/Induction Failure	CNS Site of Relapse/Induction Failure	Chloroma Site of Relapse/Induction Failure	Cytogenetic Site of Relapse/Induction Failure	Other Site of Relapse/Induction Failure	Gene Fusion	Gemtuzumab ozogamicin treatment	Refractory Timepoint sent for Induction Failure Project	Comment
TARGET-20-PAMVKZ	Male	White	Not Hispanic or Latino	5934	Relapse	517	Dead	693	2004	2005	AAML03P1	248	74	85	Yes	No	M2	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	 	NA	Unknown	Unknown	No	NA	Yes	No	No	No	Not done	Not done			No	0	CR	CR	Unknown	No	Yes	No	No	No	No	RUNX1-RUNX1T1	Gentuzumab ozogamicin treatment		"Discovery,Validation"
TARGET-20-PAMYAS	Male	White	Not Hispanic or Latino	3972	Relapse	991	Alive	3263	2004	2013	AAML03P1	5.6	63	18	No	Yes	M2	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	 	0	Other	"46,XY[20]. nuc ish AML1-ETO positive ~30% of cells consistent with a t(8;21)."	Yes	0.15	No	No	No	No	Not done	Not done	Yes	2	Yes	0.2	not in CR	CR	Standard Risk	No	Yes	No	No	No	No	RUNX1-RUNX1T1	Gentuzumab ozogamicin treatment		"Discovery,Validation"
TARGET-20-PAMYGX	Female	White	Not Hispanic or Latino	1259	Censored	3380	Alive	3380	2004	2013	AAML03P1	16	79	31	No	No	M7	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	 	1	Other	"46,XX,del(11)(q21q23)[19]/46,XX[1]"	No	NA	No	No	No	No	Not done	Not done	No	0	No	0	CR	CR	Standard Risk	No	Not Done	Not Done	Not Done	Not Done	Not Done	KMT2A-MLLT10	Gentuzumab ozogamicin treatment		"Discovery,Validation"
TARGET-20-PANAEV	Male	White	Not Hispanic or Latino	3539	Censored	2767	Alive	2767	2004	2011	AAML03P1	37.8	59	31.5	No	No	M5	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	 	0	Normal	"46,XY[24] "	No	NA	Yes	Yes	No	No	Not done	Not done	No	0	No	0	CR	CR	Low Risk	No	Not Done	Not Done	Not Done	Not Done	Not Done	NA	Gentuzumab ozogamicin treatment		"Discovery,Validation"
TARGET-20-PANBZH	Male	White	Not Hispanic or Latino	3921	Relapse	284	Dead	462	2004	2005	AAML03P1	170	85	89	No	No	M4	No	No	No	No	No	No	No	Yes	No	No	No	No	No	No	No	No	No	No	i(17)(q10)	2	inv(16)	"46,XY, inv(16)(p13.1q22),i(17)(q10)[18]  "	No	NA	No	No	No	Yes	No	No	No	0			CR	CR	Low Risk	No	No	No	Yes	No	No	CBFB-MYH11	Gentuzumab ozogamicin treatment		"Discovery,Validation"
TARGET-20-PANCSC	Female	White	Not Hispanic or Latino	3890	Relapse	725	Alive	2899	2004	2012	AAML03P1	173		97	No	No	Not classified	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	 	0	Normal	"46,XX[20]"	No	NA	No	No	Yes	No	Not done	Not done	No	0	No	0	CR	CR	Low Risk	No	Yes	No	No	No	No	NA	Gentuzumab ozogamicin treatment		"Discovery,Validation"
TARGET-20-PANDER	Female	White	Not Hispanic or Latino	4312	Relapse	1868	Alive	3291	2004	2013	AAML03P1	137	93.2	88.5	No	No	M1	No	Yes	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	 	1	t(8;21)	"46,XX,t(8;21)(q22;q22)[20]"	No	NA	Yes	No	No	No	No	No	Yes	0.1	No	0	CR	CR	Low Risk	No	Yes	No	No	No	No	RUNX1-RUNX1T1	Gentuzumab ozogamicin treatment		"Discovery,Validation"
TARGET-20-PANDIX	Male	White	Not Hispanic or Latino	6573	Relapse	728	Alive	3069	2004	2012	AAML03P1	14.1	40	3	No	No	M2	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	 	0	Normal	"46,XY[30]"	No	NA	No	No	No	No	Not done	Not done	No	0	No	0	CR	CR	Standard Risk	No	Yes	No	No	No	No	NA	Gentuzumab ozogamicin treatment		"Discovery,Validation"
TARGET-20-PANFMG	Male	White	Not Hispanic or Latino	1430	Censored	3253	Alive	3253	2004	2013	AAML03P1	65.9	91	84	No	No	M5	No	No	No	No	Yes	No	No	No	No	No	No	No	No	Yes	No	Yes	No	No	 	2	MLL	"47,XY,+8,t(9;11)(p22;q23)[20] "	No	NA	No	No	No	No	Not done	Not done					CR	CR	Standard Risk	Yes	Not Done	Not Done	Not Done	Not Done	Not Done	KMT2A-MLLT3	Gentuzumab ozogamicin treatment		"Discovery,Validation"
TARGET-20-PANGDN	Male	White	Not Hispanic or Latino	6590	Relapse	633	Alive	3063	2004	2013	AAML03P1	176.2	89	38	No	No	M5	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	 	0	Normal	"46,XY[20]"	No	NA	No	No	No	No	Not done	Not done	No	0	No	0	CR	CR	Standard Risk	No	Yes	No	No	No	No	KMT2A-MLLT4	Gentuzumab ozogamicin treatment		Discovery
TARGET-20-PANGJY	Female	White	Not Hispanic or Latino	594	Censored	2983	Alive	2983	2004	2012	AAML03P1	302	86	69	No	No	M5	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	der(15)t(1;15)(q12;q26)	1	Other	"46,XX,der(15)t(1;15)(q12;q26)[12] "	No	NA	No	No	No	No	Not done	Not done	No	0	No	0	CR	CR	Standard Risk	Yes	Not Done	Not Done	Not Done	Not Done	Not Done	NA	Gentuzumab ozogamicin treatment		"Discovery,Validation"
TARGET-20-PANGTF	Female	White	Unknown	5814	Relapse	458	Dead	616	2004	2006	AAML03P1	30.8	94.2	11	No	No	M5	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	 	0	Normal	"46,XX[20] "	No	NA	No	No	No	No	Not done	Not done			No	0	CR	CR	Standard Risk	No	Yes	No	No	No	No	NUP98-KDM5A	Gentuzumab ozogamicin treatment		"Discovery,Validation"
TARGET-20-PANHYK	Male	White	Not Hispanic or Latino	2191	Censored	1675	Alive	1675	2004	2009	AAML03P1	11.2	71	41	No	No	M2	No	Yes	No	No	No	No	No	No	No	No	No	No	No	No	No	No	Yes	No	#NAME?	2	t(8;21)	"45,X,-Y,t(8;21)(q22;q22)[20]  REPORT ONLY"	No	NA	No	No	No	No	Not done	Not done	No	0	No	0	CR	CR	Low Risk	No	Not Done	Not Done	Not Done	Not Done	Not Done	RUNX1-RUNX1T1	Gentuzumab ozogamicin treatment		"Discovery,Validation"
TARGET-20-PANINI	Male	White	Hispanic or Latino	6118	Censored	3144	Alive	3144	2004	2013	AAML03P1	16.9	86	87	No	No	Not classified	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	 	0	Normal	"46,XY"	No	NA	No	No	Yes	No	Not done	Not done			No	0	CR	CR	Low Risk	No	Not Done	Not Done	Not Done	Not Done	Not Done	NA	Gentuzumab ozogamicin treatment		"Discovery,Validation"
TARGET-20-PANKFZ	Male	White	Not Hispanic or Latino	690	Censored	3116	Alive	3116	2004	2013	AAML03P1	64.1	50	45	No	No	Not classified	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	 	NA	Unknown	Unknown	No	NA	Yes	No	No	No	Not done	Not done					CR	CR	Unknown	No	Not Done	Not Done	Not Done	Not Done	Not Done	NA	Gentuzumab ozogamicin treatment		"Discovery,Validation"
TARGET-20-PANKKE	Male	White	Hispanic or Latino	261	Relapse	269	Alive	3149	2004	2013	AAML03P1	125.9	52	50	No	No	M4	No	No	No	No	No	No	No	Yes	No	No	No	No	No	No	No	No	No	No	 	1	inv(16)	"46,XY,inv(16)(p13.1q22)[18] [report only]"	No	NA	No	No	No	No	Not done	Not done	No	0	Yes	1.8	CR	CR	Low Risk	No	Yes	Yes	No	No	No	CBFB-MYH11	Gentuzumab ozogamicin treatment		"Discovery,Validation"
TARGET-20-PANKNB	Male	Black or African American	Not Hispanic or Latino	6460	Censored	443	Alive	443	2004	2006	AAML03P1	81.5	95.3	84	No	No	M4	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	 	0	Normal	"46,XY[35] REPORT ONLY"	No	NA	No	No	No	No	Not done	Not done	No	0	No	0	CR	CR	Standard Risk	No	Not Done	Not Done	Not Done	Not Done	Not Done	KMT2A-MLLT3	Gentuzumab ozogamicin treatment		"Discovery,Validation"
TARGET-20-PANLIR	Male	Native Hawaiian or other Pacific Islander	Not Hispanic or Latino	5885	Relapse	425	Alive	3238	2005	2013	AAML03P1	45.3	21	33	No	No	M2	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	 	0	Normal	"46,Xy[20]"	No	NA	No	No	Yes	No	Not done	Not done	Yes	2	No	0	CR	CR	Low Risk	No	Yes	No	No	No	No	NA	Gentuzumab ozogamicin treatment		Discovery
TARGET-20-PANLIZ	Male	Black or African American	Not Hispanic or Latino	3102	Relapse	329	Dead	784	2005	2007	AAML03P1	6.4	90	39	No	No	Not classified	No	Yes	No	No	No	No	No	No	No	No	No	No	No	Yes	No	No	No	No	 	2	t(8;21)	"47,XY,+8,t(8;21)(q22;q22)[13]/46,XY[7] "	NO	NA	NO	NO	NO	NO	NO	NO	No	0			CR	CR	Low Risk	No	Yes	No	No	No	No	RUNX1-RUNX1T1	Gentuzumab ozogamicin treatment		Discovery
TARGET-20-PANLJN	Male	White	Hispanic or Latino	6524	Censored	2133	Alive	2133	2005	2010	AAML03P1	11.8	88	45	No	No	M1	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	 	0	Normal	"46,XY[20] "	No	NA	Yes	Yes	No	No	Not done	Not done	No	0	No	0	CR	CR	Low Risk	No	Not Done	Not Done	Not Done	Not Done	Not Done	NA	Gentuzumab ozogamicin treatment		"Discovery,Validation"
TARGET-20-PANLKB	Female	White	Not Hispanic or Latino	1678	Censored	1985	Alive	1985	2005	2010	AAML03P1	97.6	74.6	74	No	No	M5	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	add(15)(q26)	1	Other	"46,XX,add(15)(q26)[7]/46,XX[4]  REPORT ONLY "	No	NA	No	No	No	No	Not done	Not done	No	0	No	0	CR	CR	Standard Risk	No	Not Done	Not Done	Not Done	Not Done	Not Done	NA	Gentuzumab ozogamicin treatment		"Discovery,Validation"
TARGET-20-PANLLX	Male	Native Hawaiian or other Pacific Islander	Not Hispanic or Latino	4559	Relapse	614	Alive	3234	2005	2013	AAML03P1	2.1	25	0	No	No	M2	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	 	0	Normal	"46,XY[20]"	No	NA	No	No	No	No	Not done	Not done	Yes	0.8			CR	unevaluable	Standard Risk	No	Yes	No	No	No	No	NA	Gentuzumab ozogamicin treatment		"Discovery,Validation"
TARGET-20-PANLXM	Female	Asian	Not Hispanic or Latino	3748	Relapse	284	Dead	390	2005	2006	AAML03P1	11.2	54	65	No	No	M2	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	 	0	Normal	"46,XX[20] "	Yes	0.22	No	No	No	No	Not done	Not done	No	0	No	0	CR	CR	Standard Risk	No	Yes	No	No	No	No	NUP98-HMGB3	Gentuzumab ozogamicin treatment		"Discovery,Validation"
TARGET-20-PANNHB	Female	Black or African American	Not Hispanic or Latino	1482	Relapse	366	Dead	436	2005	2006	AAML03P1	19.4	58	63	No	No	M2	No	Yes	No	No	No	No	No	No	No	Yes	No	No	No	No	No	No	No	Yes	#NAME?	3	t(8;21)	"46,XX,del(7)(q32q34),t(8;21)(q22;q22)[17]/45,idem,-X[3] REPORT ONLY"	NO	NA	No	NO	NO	NO	Not done	Not done	Yes	0.9	Yes	1.6	CR	CR	Low Risk	No	Yes	No	No	No	No	RUNX1-RUNX1T1	Gentuzumab ozogamicin treatment		"Discovery,Validation"
TARGET-20-PANPKN	Male	White	Hispanic or Latino	359	Censored	3630	Alive	3630	2005	2015	AAML03P1	120.7	71	63	No	No	M5	No	No	No	No	Yes	No	No	No	No	No	No	No	No	No	No	Yes	No	No	 	1	MLL	"46,XY,t(9;11)(p22;q23)[20]  REPORT ONLY"	No	NA	No	No	No	No	Not done	Not done	No	0	No	0	CR	CR	Standard Risk	No	Not Done	Not Done	Not Done	Not Done	Not Done	KMT2A-MLLT3	Gentuzumab ozogamicin treatment		"Discovery,Validation"
TARGET-20-PANPTM	Male	White	Not Hispanic or Latino	5853	Relapse	342	Alive	3130	2005	2013	AAML03P1	86.7	72	47	No	No	M4	No	No	No	No	No	No	No	Yes	No	No	No	No	No	No	No	No	No	No	 	1	inv(16)	"46,XY,inv(16)(p13.1q22)[20] "	No	NA	No	No	No	No	No	No	No	0	No	0	CR	CR	Low Risk	No	Yes	No	No	No	No	CBFB-MYH11	Gentuzumab ozogamicin treatment		"Discovery,Validation"
TARGET-20-PANSBH	Male	White	Hispanic or Latino	491	Relapse	523	Dead	813	2005	2007	AAML03P1	11.5	93	19	No	No	M0 Undifferentiated	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	ider(16)(q10)del(16)(q22)	1	Other	"46,XY,ider(16)(q10)del(16)(q22)[[30] "	No	NA	No	No	No	No	Not done	Not done	No	0	No	0	CR	CR	Standard Risk	No	Yes	No	No	No	No	FUS-FEV	Gentuzumab ozogamicin treatment		"Discovery,Validation"
TARGET-20-PANSJB	Male	Unknown	Hispanic or Latino	4074	Relapse	297	Dead	422	2005	2006	AAML03P1	24.3	70	61	No	No	Not classified	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	 	0	Normal	"46,XY[20]"	Yes	0.74	No	No	No	No	Not done	Not done	No	0	No	0	CR	CR	High Risk	No	Yes	No	No	No	No	NA	Gentuzumab ozogamicin treatment		"Discovery,Validation"
TARGET-20-PANTNA	Male	White	Not Hispanic or Latino	6416	Relapse	311	Dead	1152	2005	2008	AAML03P1	23.7	65	84	No	No	M2	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	"der(1)t(1;1)(q42;p22),der(1)t(1;1)(p34;q21),t(11;16)(q25;p11.2),del(13)(q12q22)"	4	Other	"46,XY,der(1)t(1;1)(q42;p22),der(1)t(1;1)(p34;q21),t(6;9)(p25;p22)c,t(11;16)(q25;p11.2)[9]/46,idem,del(13)(q12q22)[10]"	No	NA	No	No	No	No	Not done	Not done			Yes	0.8	CR	CR	Standard Risk	No	Yes	Yes	No	No	No	FUS-FLI1	Gentuzumab ozogamicin treatment		"Discovery,Validation"
TARGET-20-PANTPW	Female	White	Not Hispanic or Latino	821	Censored	2946	Alive	2946	2005	2013	AAML03P1	152.6	91.5	89	No	No	M1	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	 	0	Normal	"46,XX[20] [REPORT ONLY]"	No	NA	No	No	Yes	No	Not done	Not done	No	0	No	0	CR	CR	Low Risk	Yes	Not Done	Not Done	Not Done	Not Done	Not Done	CBFA2T3-GLIS2	Gentuzumab ozogamicin treatment		"Discovery,Validation"
TARGET-20-PANUTB	Female	White	Not Hispanic or Latino	5587	Relapse	763	Dead	925	2005	2008	AAML03P1	127.8	90	95	No	No	M2	No	No	No	No	No	No	No	Yes	No	No	No	No	No	No	No	No	No	No	 	1	inv(16)	"46,XX,inv(16)(p13q22)23]/46,XX[2]"	No	NA	No	No	No	No	Yes	No	No	0	No	0	CR	CR	Low Risk	No	Yes	No	No	No	No	CBFB-MYH11	Gentuzumab ozogamicin treatment		"Discovery,Validation"
TARGET-20-PANUUA	Female	White	Not Hispanic or Latino	5405	Relapse	462	Dead	1767	2005	2010	AAML03P1	76.6	60	77	No	No	M4	No	No	No	No	No	No	No	Yes	No	No	No	No	No	No	No	No	No	No	t(17;19)(q11.2;q13.3)	2	inv(16)	"46,XX,inv(16)(p13.1q22)[16]/46,idem,t(17;19)(q11.2;q13.3)[4]  REPORT ONLY"	No	NA	No	No	No	No	Not done	Not done	No	0	No	0	CR	CR	Low Risk	No	Yes	No	No	No	No	CBFB-MYH11	Gentuzumab ozogamicin treatment		"Discovery,Validation"
TARGET-20-PANVGE	Male	White	Not Hispanic or Latino	5346	Censored	2819	Alive	2819	2005	2013	AAML03P1	54.8	85	70	No	No	Not classified	No	No	No	No	No	No	No	Yes	No	No	No	No	No	No	No	No	No	No	22	2	inv(16)	"47,XY,inv(16)(p13.1q22),+22[20] "	No	NA	Yes	No	No	Yes	Not done	Not done	Yes	2	Yes	0.8	CR	CR	Low Risk	No	Not Done	Not Done	Not Done	Not Done	Not Done	CBFB-MYH11	Gentuzumab ozogamicin treatment		"Discovery,Validation"
TARGET-20-PANWHP	Female	White	Not Hispanic or Latino	1852	Censored	2738	Alive	2738	2005	2013	AAML03P1	77.2	61	59	No	No	M4	No	No	No	No	No	No	No	Yes	No	No	No	No	No	No	No	No	No	No	 	1	inv(16)	"46,XX,inv(16)(p13.1q22)[16]/46,XX[4] "	No	NA	No	No	No	No	No	Yes	No	0	No	0	CR	CR	Low Risk	No	Not Done	Not Done	Not Done	Not Done	Not Done	CBFB-MYH11	Gentuzumab ozogamicin treatment		"Discovery,Validation"
TARGET-20-PANZKA	Female	White	Not Hispanic or Latino	637	Censored	2824	Alive	2824	2005	2013	AAML03P1	11.1	99	35	No	No	M5	No	No	No	No	Yes	No	No	No	No	No	No	No	No	No	No	Yes	No	No	 	1	MLL	"46,XX,t(9;11)(p22;q23)[22] "	No	NA	No	No	No	No	Not done	Not done	No	0	No	0	CR	CR	Standard Risk	No	Not Done	Not Done	Not Done	Not Done	Not Done	KMT2A-MLLT3	Gentuzumab ozogamicin treatment		"Discovery,Validation"
TARGET-20-PAPAWN	Male	White	Hispanic or Latino	2154	Censored	2605	Alive	2605	2005	2012	AAML03P1	253.2	71	77	No	No	M4	No	No	No	No	No	No	No	Yes	No	No	No	No	No	No	No	No	No	No	 	1	inv(16)	"46,XY,inv(16)(p13.1q22)[14]/46,XY[16] "	No	NA	NO	NO	NO	NO	NO	NO	No	0	No	0	CR	CR	Low Risk	No	Not Done	Not Done	Not Done	Not Done	Not Done	CBFB-MYH11	Gentuzumab ozogamicin treatment		"Discovery,Validation"
TARGET-20-PAPBEJ	Female	Black or African American	Not Hispanic or Latino	367	Relapse	263	Dead	404	2005	2006	AAML03P1	60.3	50	55	No	No	M5	No	No	No	No	No	No	No	No	No	Yes	No	No	No	No	No	No	No	No	"der(6)t(6;12;7)(p12;p13;p22),der(7)t(6;12;7)del(7)(q11.2),der(12)t(6;12;7),r(9)(p12q12),+19"	4 or more	Other	"47,XX,der(6)t(6;12;7)(p12;p13;p22),der(7)t(6;12;7)del(7)(q11.2),der(12)t(6;12;7),r(9)(p12q12),+19[16]46,idem,-r(9)[3]/46,XX[1] "	No	NA	No	No	No	No	Not done	Not done	No	0	No	0	CR	CR	Standard Risk	No	Yes	Yes	No	No	No	NUP98-KDM5A	Gentuzumab ozogamicin treatment		"Discovery,Validation"
TARGET-21-PAMYMA	Male	White	Not Hispanic or Latino	450	Induction Failure	28	Dead	378	2004	2005	AAML03P1	237	89	69	No	No	M4	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	t(X;11)(q13;p15.1)	1	Other	"46,Y,t(X;11)(q13;p15.1)[18]/46,XY[2]  "	No	NA	No	No	No	No	Not done	Not done	Yes	30			not in CR	not in CR	Standard Risk	Unknown	Yes	No	No	No	No	NA	Gentuzumab ozogamicin treatment	EOI I	Induction Failure
TARGET-21-PANVPB	Male	White	Not Hispanic or Latino	5338	Induction Failure	77	Dead	421	2005	2006	AAML03P1	34.1	87.3	88	Yes	No	M5	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	10	1	Other	"47,XY,+10[14]/46,XY[6] "	No	NA	No	No	No	No	Not done	Not done					not in CR	not in CR	Standard Risk	Unknown	Yes	No	No	No	No	NA	Gentuzumab ozogamicin treatment	no refractory sample sent	Induction Failure
TARGET-21-PANZLR	Female	Black or African American	Not Hispanic or Latino	4793	Induction Failure	28	Dead	74	2005	2005	AAML03P1	114.7	87	90	No	No	Not classified	No	No	No	No	No	No	No	No	No	No	No	No	No	Yes	No	No	No	No	 	1	Other	"47,XX,+8[20] "	No	NA	No	No	No	No	Not done	Not done	Yes	.			not in CR	not in CR	Standard Risk	Unknown	Yes	No	No	No	No	NUP98-NSD1	Gentuzumab ozogamicin treatment	EOI I	Induction Failure
TARGET-20-PAPVCN	Male	White	Not Hispanic or Latino	4231	Relapse	486	Alive	2592	2006	2013	AAML0531	62.2	75	51	No	No	M4	No	No	No	No	No	No	No	Yes	No	No	No	No	No	No	No	No	No	No	 	1	inv(16)	"46,XY,inv(16)(p13.1q22)[20]"	No	NA	No	No	No	No	Yes	No	No	0			CR	CR	Low Risk	No	Yes	No	No	No	No	CBFB-MYH11	Gentuzumab ozogamicin treatment		"Discovery,Validation,TMA"
TARGET-20-PAPVZK	Male	White	Not Hispanic or Latino	5822	Relapse	541	Alive	2492	2006	2013	AAML0531	146	100	66	No	No	M4	No	No	No	No	No	No	No	Yes	No	No	No	No	No	No	No	No	No	No	 	1	inv(16)	"46,XY,inv(16)(p13.1q22)[20]"	No	NA	No	No	No	No	Yes	No	No	0	No	0	CR	CR	Low Risk	No	Yes	No	No	Yes	No	CBFB-MYH11	Gentuzumab ozogamicin treatment		"Discovery,Validation,TMA"
TARGET-20-PAPWHS	Male	White	Not Hispanic or Latino	4852	Censored	2687	Alive	2687	2006	2014	AAML0531	81.2	36	63	No	Yes	M2	No	Yes	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	 	1	t(8;21)	"46,XY,t(8;21)(q22;q22)[21]"	No	NA	No	No	No	No	No	No	No	0	No	0	CR	CR	Low Risk	No	Not Done	Not Done	Not Done	Not Done	Not Done	RUNX1-RUNX1T1	NO Gentuzumab ozogamicin treatment		"Discovery,Validation,TMA"
TARGET-20-PAPWIU	Female	American Indian or Alaska Native	Not Hispanic or Latino	4421	Censored	2829	Alive	2829	2006	2014	AAML0531	52.2	75	86	No	No	M1	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	 	0	Normal	"46,XX"	No	NA	No	No	Yes	No	Not done	Not done					CR	CR	Low Risk	No	Not Done	Not Done	Not Done	Not Done	Not Done	NA	Gentuzumab ozogamicin treatment		"Discovery,Validation,TMA"
TARGET-20-PAPWYK	Female	White	Not Hispanic or Latino	8231	Death	199	Dead	199	2006	2007	AAML0531	66.1	36	36	No	No	M4	No	No	No	No	No	No	No	Yes	No	No	No	No	No	No	No	No	No	No	 	1	inv(16)	"46,XX,inv(16)(p13.1q22)[20]"	No	NA	No	No	No	No	No	No	No	0	No	0	CR	CR	Low Risk	No	Not Done	Not Done	Not Done	Not Done	Not Done	CBFB-MYH11	Gentuzumab ozogamicin treatment		"Discovery,Validation,TMA"
TARGET-20-PAPXRJ	Female	Black or African American	Not Hispanic or Latino	2855	Relapse	392	Dead	1248	2008	2010	AAML0531	22.9	29	13	No	No	M2	Yes	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	idic(9)(q11)	2	Other	"46,XX,t(6;9)(p23;q34)[12]/46,XX,der(6)t(6;9)(p23;q34),idic(9)(q11)[7]/46,XX[1]"	No	NA	No	No	No	No	Not done	Not done	No	0			CR	CR	Standard Risk	No	Yes	No	No	No	No	DEK-NUP214	Gentuzumab ozogamicin treatment		"Discovery,Validation,TMA"
TARGET-20-PAPXWI	Female	White	Not Hispanic or Latino	1430	Relapse	410	Alive	880	2006	2009	AAML0531	128.7	89	74	No	No	M4	No	No	No	No	No	No	No	Yes	No	No	No	No	No	No	No	No	No	No	 	1	inv(16)	"46,XX,inv(16)(p13.1q22)[20]"	No	NA	No	No	No	No	No	Yes	No	0	No	0	CR	CR	Low Risk	No	Yes	Yes	No	Yes	No	CBFB-MYH11	Gentuzumab ozogamicin treatment		"Discovery,Validation,TMA"
TARGET-20-PARAJX	Male	White	Not Hispanic or Latino	618	Censored	2803	Alive	2803	2007	2014	AAML0531	42	70	80	No	No	Unknown	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	"+15, t(20;21)(q11.2;q22)"	2	Other	"47,XY,+15,t(20;21)(q11.2;q22)[19]/46,XY[1]"	No	NA	No	No	No	No	Not done	Not done	No	0.04	No	0	CR	CR	Standard Risk	No	Not Done	Not Done	Not Done	Not Done	Not Done	RUNX1-CBFA2T2	NO Gentuzumab ozogamicin treatment		"Discovery,Validation,TMA"
TARGET-20-PARANT	Male	White	Not Hispanic or Latino	6397	Censored	2509	Alive	2509	2007	2013	AAML0531	5.1	31	40	No	No	M2	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	 	0	Normal	"46,XY[29]"	No	NA	No	No	No	No	Not done	Not done			No	0	CR	CR	Standard Risk	Yes	Not Done	Not Done	Not Done	Not Done	Not Done	NA	Gentuzumab ozogamicin treatment		"Discovery,Validation,TMA"
TARGET-20-PARBFJ	Male	White	Not Hispanic or Latino	4701	Censored	2387	Alive	2387	2007	2013	AAML0531	46.1	86	57	No	No	M4	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	 	0	Normal	"46,XY[60]"	No	NA	Yes	Yes	No	No	Not done	Not done					CR	CR	Low Risk	No	Not Done	Not Done	Not Done	Not Done	Not Done	NA	Gentuzumab ozogamicin treatment		"Discovery,Validation,TMA"
TARGET-20-PARBIU	Female	White	Not Hispanic or Latino	5830	Relapse	809	Dead	917	2007	2009	AAML0531	16.5	99	77	No	No	M5	No	No	No	No	Unknown	No	No	No	No	No	No	No	No	No	No	Yes	No	No	 	1	MLL	Inadequate. ish MLL sep	No	NA	No	No	No	No	Not done	Not done	No	0	No	0	CR	CR	Standard Risk	No	Yes	No	No	No	No	KMT2A-MLLT3	NO Gentuzumab ozogamicin treatment		"Discovery,Validation,TMA"
TARGET-20-PARBRA	Female	White	Not Hispanic or Latino	2792	Relapse	637	Dead	1362	2007	2010	AAML0531	73.6	78	35	No	No	M5	No	No	No	No	No	Yes	No	No	No	No	No	No	No	No	No	Yes	No	No	 	1	MLL	"46,XX,t(10;11)(p11.2;q23)[20]"	No	NA	No	No	No	No	Not done	Not done			No	0	CR	CR	Standard Risk	No	Yes	No	No	Yes	No	KMT2A-MLLT10	Gentuzumab ozogamicin treatment		"Discovery,Validation,TMA"
TARGET-20-PARCUK	Female	White	Not Hispanic or Latino	5987	Relapse	203	Dead	279	2007	2008	AAML0531	23.9	96	63	No	No	M4	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	 	4	Other	"46,XX,del(10)(q22q24),t(11;11)(p15;q13.1),-16,+mar[16]/46,XX[4],"	No	NA	No	No	No	No	Not done	Not done	No	0	No	0	CR	CR	Standard Risk	No	Yes	No	Yes	No	No	NA	Gentuzumab ozogamicin treatment		"Discovery,Validation,TMA"
TARGET-20-PARCVS	Male	White	Not Hispanic or Latino	5600	Relapse	662	Alive	2536	2007	2014	AAML0531	15.6	64.4	54	No	No	M2	No	Yes	No	No	No	No	No	No	No	No	No	No	No	No	No	No	Yes	No	"-Y, i(21q) complex"	3	t(8;21)	"44,X,-Y,der(8)t(8;21)(q22;q22),-21,der(21)t(8;21)(q22;q22)i(21)(q10)[20]"	No	NA	No	No	No	No	No	Yes	No	0	No	0	CR	CR	Low Risk	No	Yes	No	No	No	No	RUNX1-RUNX1T1	NO Gentuzumab ozogamicin treatment		"Discovery,Validation"
TARGET-20-PARCZL	Female	White	Hispanic or Latino	3806	Relapse	985	Alive	2695	2007	2014	AAML0531	94.8	50.5	37	Yes	Yes	M2	No	Yes	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	 	2	t(8;21)	"46,XX,t(15;21)(q22;q22), cryp ins(8;21)(q22;q22q22)[19].ish der(8)ins(8;21)(q22;q22)(ETO+,RUNX1+)"	No	NA	No	No	No	No	No	No	No	0	No	0	not in CR	CR	Low Risk	No	Yes	No	No	No	No	RUNX1-RUNX1T1	Gentuzumab ozogamicin treatment		"Discovery,Validation,TMA"
TARGET-20-PARDDY	Male	White	Not Hispanic or Latino	677	Relapse	247	Dead	766	2007	2009	AAML0531	115	80	79	No	No	M1	No	No	No	No	No	No	No	No	No	No	No	No	No	No	Yes	No	No	No	"5p-, i(7q),14q+,+21"	4	Other	"47,XY,del(5)(p15.1),i(7)(q10),add(14)(q32),+21[21]"	No	NA	No	No	No	No	Not done	Not done	Yes	16	No	0	not in CR	CR	Standard Risk	No	Yes	No	No	No	No	NA	NO Gentuzumab ozogamicin treatment		"Discovery,Validation,TMA"
TARGET-20-PARDMG	Female	White	Not Hispanic or Latino	6535	Relapse	287	Dead	413	2007	2008	AAML0531	54.8	57	62	No	No	M4	No	No	No	No	No	No	No	Yes	No	No	No	No	No	No	No	No	No	No	 	1	inv(16)	"46,XX,inv(16)(p13.1q22)[20]"	Yes	0.15	No	No	No	No	No	No	No	0	No	0	CR	CR	Low Risk	No	Yes	No	No	No	No	CBFB-MYH11	NO Gentuzumab ozogamicin treatment		"Discovery,Validation,TMA"
TARGET-20-PARENB	Female	Other	Hispanic or Latino	2758	Censored	314	Alive	314	2007	2008	AAML0531	31.7	80	83	No	Unknown	M2	No	Yes	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	Yes	 	2	t(8;21)	"45,X,-X,t(8;21)(q22;q22)[20]"	No	NA	No	No	No	No	No	Yes	Yes	3	Yes	1	not in CR	CR	Low Risk	No	Not Done	Not Done	Not Done	Not Done	Not Done	RUNX1-RUNX1T1	NO Gentuzumab ozogamicin treatment		"Discovery,Validation,TMA"
TARGET-20-PARFAL	Male	White	Not Hispanic or Latino	6922	Relapse	256	Dead	378	2007	2008	AAML0531	11.7	69	43	No	No	Unknown	No	No	No	No	No	Yes	No	No	No	No	No	No	No	No	No	Yes	No	No	 	6	MLL	"47,XY,t(10;11)(p13;q21),+19[2]/46,idem,der(7;11)(q10;q10)[4]/46,idem,psu dic(7;11)(p22;p11.2)[4]/46,idem,der(7;19)(q10;q10),+mar[4]/46,XY[5]"	No	NA	No	No	No	No	Not done	Not done					CR	CR	Standard Risk	No	Yes	No	No	No	No	MLLT10-PICALM	NO Gentuzumab ozogamicin treatment		"Discovery,Validation,TMA"
TARGET-20-PARHVK	Female	White	Not Hispanic or Latino	4983	Relapse	376	Alive	2516	2007	2014	AAML0531	24.2	92	93	No	No	M1	No	No	No	Yes	No	No	No	No	No	No	No	No	No	No	No	Yes	No	No	 	1	MLL	"46,XX,ins(6;11)(q27;q22q23.3)[17]/46,XX[3]"	No	NA	No	No	No	No	Not done	Not done	No	0	No	0	CR	CR	Standard Risk	No	Yes	No	No	No	No	KMT2A-MLLT4	NO Gentuzumab ozogamicin treatment		"Discovery,Validation,TMA"
TARGET-20-PARJCR	Male	Unknown	Unknown	5348	Relapse	318	Dead	468	2007	2008	AAML0531	1.3	86.2	12	No	No	M5	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	Yes	No	No	 	1	MLL	"46,XX,cryp add(11)(q23). ish MLL sep (del 3'MLL)"	No	NA	No	No	No	No	Not done	Not done	Yes	4.1	Yes	0.1	CR	CR	Standard Risk	No	Yes	No	No	No	No	KMT2A-MLLT4	NO Gentuzumab ozogamicin treatment		"Discovery,Validation"
TARGET-20-PARKCX	Female	White	Not Hispanic or Latino	292	Censored	2760	Alive	2760	2007	2015	AAML0531	382.5	92	92	No	No	M5	No	No	No	No	Yes	No	No	No	No	No	No	No	No	No	No	Yes	No	No	 	1	MLL	"46,XX,t(9;11)(p22;q23)[20]"	No	NA	No	No	No	No	Not done	Not done	No	0	No	0	CR	CR	Standard Risk	No	Not Done	Not Done	Not Done	Not Done	Not Done	KMT2A-MLLT3	Gentuzumab ozogamicin treatment		"Discovery,Validation,TMA"
TARGET-20-PARLVL	Male	Black or African American	Not Hispanic or Latino	963	Relapse	299	Dead	1979	2007	2013	AAML0531	178.2	90	87	No	No	M2	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	 	0	Normal	"46,XY[20]"	No	NA	No	No	Yes	No	Not done	Not done	Yes	5	No	0	CR	CR	Low Risk	No	Yes	No	No	No	No	NA	Gentuzumab ozogamicin treatment		"Discovery,Validation,TMA"
TARGET-20-PARMZF	Female	White	Not Hispanic or Latino	3163	Relapse	294	Alive	2193	2007	2013	AAML0531	200.1	90	62	No	No	M4	No	No	No	No	No	No	No	Yes	No	No	No	No	No	No	No	No	No	No	 	1	inv(16)	"46,XX,inv(16)(p13.1q22)[20]"	No	NA	No	No	No	No	Yes	No	No	0	No	0	CR	CR	Low Risk	No	Yes	No	No	No	No	CBFB-MYH11	NO Gentuzumab ozogamicin treatment		"Discovery,Validation,TMA"
TARGET-20-PARPDS	Female	White	Not Hispanic or Latino	3774	Relapse	550	Dead	836	2007	2010	AAML0531	2.1	70	9	No	No	Unknown	No	No	No	No	No	No	No	No	No	No	No	No	No	Yes	No	No	No	No	"+X,+10,+19,+21,dup(12q)"	More than 6	Other	"48,XX,+X,+8[3]/51,XX,+X,+X,+10,dup(12)(q13q15),+19,+21[2]/46,XX[3] "	No	NA	No	No	No	No	Not done	Not done	No	0	No	0	CR	CR	Standard Risk	No	Yes	No	No	No	No	NA	Gentuzumab ozogamicin treatment		"Discovery,Validation"
TARGET-20-PARPWL	Male	Black or African American	Not Hispanic or Latino	766	Censored	1199	Alive	1199	2007	2011	AAML0531	134.5	77	40	No	No	M4	No	No	No	No	No	No	No	Yes	No	No	No	No	No	Yes	No	No	No	No	22	3	inv(16)	"47,XY,inv(16)(p13.1q22),+22[13]/48,idem,+8[2] "	No	NA	No	No	No	No	No	No	No	0	No	0	CR	CR	Low Risk	No	Not Done	Not Done	Not Done	Not Done	Not Done	CBFB-MYH11	Gentuzumab ozogamicin treatment		"Discovery,Validation,TMA"
TARGET-20-PARTAL	Female	White	Not Hispanic or Latino	6000	Relapse	384	Dead	531	2008	2009	AAML0531	70.5	66	16	No	No	M4	No	No	No	No	No	No	No	Yes	No	No	No	No	No	No	No	No	No	No	 	1	inv(16)	"46,XX,inv(16)(p13.1q22)[20]"	No	NA	No	No	No	No	No	No	No	0	No	0	CR	CR	Low Risk	No	Yes	No	No	Yes	No	CBFB-MYH11	NO Gentuzumab ozogamicin treatment		"Discovery,Validation,TMA"
TARGET-20-PARUBT	Female	White	Not Hispanic or Latino	2692	Relapse	293	Dead	586	2008	2009	AAML0531	7.7	96	0	No	No	Unknown	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	 	0	Normal	"46,XX[20]"	No	NA	No	No	No	No	Not done	Not done	No	0	No	0	CR	CR	Standard Risk	No	Yes	No	No	No	No	NA	Gentuzumab ozogamicin treatment		"Discovery,Validation,TMA"
TARGET-20-PARUNX	Female	White	Not Hispanic or Latino	2321	Relapse	690	Alive	2364	2008	2014	AAML0531	14.9	87	82	No	No	M1	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	"der(6)t(1;6)(q21;q27),t(7;12)(q36;p13),+19"	3	Other	"48,XX,+der(6)t(1;6)(q21;q27),t(7;12)(q36;p13),+19[18] [t(7;12) nuc ish ETV6 sep] "	No	NA	No	No	No	No	Not done	Not done	No	0	No	0	CR	CR	Standard Risk	No	Yes	No	No	No	No	MNX1-ETV6	Gentuzumab ozogamicin treatment		"Discovery,Validation"
TARGET-20-PARUTH	Male	White	Not Hispanic or Latino	3454	Relapse	488	Dead	1412	2008	2011	AAML0531	42.5	61	71	Yes	Yes	Unknown	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	 	0	Normal	"46,XY[20].nuc ish CBFBx3[22%]"	No	NA	Yes	No	No	No	Not done	Not done	No	0	No	0	CR	CR	Standard Risk	No	Yes	No	No	No	No	NA	Gentuzumab ozogamicin treatment		"Discovery,Validation,TMA"
TARGET-20-PARUUB	Female	White	Not Hispanic or Latino	6315	Censored	1882	Alive	1882	2008	2013	AAML0531	31	99	62	No	No	M2	No	Yes	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	Yes	#NAME?	2	t(8;21)	"45,X,-X,t(8;21)(q22;q22)[20] "	No	NA	No	No	No	No	No	No	No	0			CR	CR	Low Risk	No	Not Done	Not Done	Not Done	Not Done	Not Done	RUNX1-RUNX1T1	NO Gentuzumab ozogamicin treatment		"Discovery,Validation,TMA"
TARGET-20-PARUWX	Male	White	Not Hispanic or Latino	1049	Relapse	228	Dead	439	2008	2009	AAML0531	112.5	90	65	No	No	M1	No	No	No	No	No	No	No	No	No	No	No	No	No	Yes	No	No	No	No	 	1	Other	"47,XY,+8[5]/46,XY[23]"	Yes	0.54	No	No	No	Yes	Not done	Not done	Yes	3	Yes	0.1	CR	CR	High Risk	Yes	Yes	Yes	No	No	No	NA	Gentuzumab ozogamicin treatment		"Discovery,Validation,TMA"
TARGET-20-PARWDZ	Female	White	Not Hispanic or Latino	4855	Relapse	261	Dead	321	2008	2009	AAML0531	137	76.5	91	No	No	M5	No	No	No	No	Yes	No	No	No	No	No	No	No	No	No	No	Yes	No	No	der(1;5)(q10;p10)	2	MLL	"47,XX,+der(1;5)(q10;p10),t(9;11)(p22;q23)[20] "	No	NA	No	No	No	No	Not done	Not done			No	0	CR	CR	Standard Risk	No	Yes	No	No	No	No	KMT2A-MLLT3	Gentuzumab ozogamicin treatment		"Discovery,Validation,TMA"
TARGET-20-PARXBT	Male	White	Not Hispanic or Latino	3381	Censored	2246	Alive	2246	2008	2014	AAML0531	34.9	68	68	No	No	M4	No	No	No	No	No	No	No	Yes	No	No	No	No	No	No	No	No	No	No	 	1	inv(16)	"46,XY,inv(16)(p13.1q22)[20] "	No	NA	No	No	No	No	No	No	No	0	No	0	not in CR	CR	Low Risk	No	Not Done	Not Done	Not Done	Not Done	Not Done	CBFB-MYH11	NO Gentuzumab ozogamicin treatment		"Discovery,Validation"
TARGET-20-PARXMP	Male	White	Not Hispanic or Latino	534	Censored	1903	Alive	1903	2008	2013	AAML0531	8.7	35	3	No	No	M6	No	No	No	No	No	No	No	No	No	No	No	No	No	No	Yes	No	No	No	21	5	Other	"48,XY,der(3)t(3;13)(p24;q14),+6,der(6)t(3;6)(p23;q23)x2,der(13)t(6;13)(q 23;q12),+21[6]/46,XY[14]"	No	NA	No	No	No	No	Not done	Not done	No	0	No	0	CR	CR	Standard Risk	No	Not Done	Not Done	Not Done	Not Done	Not Done	NUP98-KDM5A	Gentuzumab ozogamicin treatment		"Discovery,Validation,TMA"
TARGET-20-PARXNG	Male	Black or African American	Not Hispanic or Latino	3687	Censored	2246	Alive	2246	2008	2014	AAML0531	137	62.5	95	No	No	M2	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	 	0	Normal	"46,XY[21]"	No	NA	No	No	Yes	No	Not done	Not done					CR	CR	Low Risk	Yes	Not Done	Not Done	Not Done	Not Done	Not Done	NA	NO Gentuzumab ozogamicin treatment		"Discovery,Validation,TMA"
TARGET-20-PARYFN	Female	White	Not Hispanic or Latino	1597	Relapse	655	Alive	2203	2008	2014	AAML0531	87.8	90	67.9	No	No	M4	No	No	No	No	No	No	No	Yes	No	No	No	No	No	No	No	No	No	No	 	1	inv(16)	"46,XX,inv(16)(p13.1q22)[2] "	No	NA	No	No	No	No	Yes	No	Yes	0.3	No	0	CR	CR	Low Risk	No	Yes	No	No	Yes	No	CBFB-MYH11	Gentuzumab ozogamicin treatment		"Discovery,Validation,TMA"
TARGET-20-PARYGA	Male	White	Not Hispanic or Latino	5916	Censored	2406	Alive	2406	2008	2014	AAML0531	59.8	62.3	70	No	No	M4	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	 	0	Normal	"46,XY[20]"	No	NA	No	No	No	No	Not done	Not done			No	0	CR	CR	Standard Risk	Yes	Not Done	Not Done	Not Done	Not Done	Not Done	NUP98-HMGB3	Gentuzumab ozogamicin treatment		"Discovery,Validation"
TARGET-20-PARYVW	Female	White	Hispanic or Latino	664	Relapse	348	Alive	2317	2008	2014	AAML0531	19.4	83	27.4	No	No	Not classified	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	t(2;12)(q33;p13)	4	Other	"90,XXXX,t(2;12)(q33;p13)x2,-15,-18[28]"	No	NA	No	No	No	No	Not done	Not done	Yes	0.1	Yes	0.1	not in CR	CR	Standard Risk	No	Yes	No	No	Yes	No	ETV6-INO8D	NO Gentuzumab ozogamicin treatment		"Discovery,Validation"
TARGET-20-PARZUU	Male	White	Not Hispanic or Latino	3273	Relapse	558	Alive	2168	2008	2014	AAML0531	113	95	78	No	No	M1	No	Yes	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	 	1	t(8;21)	"46,XY,t(8;21)(q22;q22)[20]"	No	NA	No	No	No	No	Yes	Yes	Yes	2.7			CR	CR	Low Risk	No	Yes	No	No	No	No	RUNX1-RUNX1T1	NO Gentuzumab ozogamicin treatment		"Discovery,Validation,TMA"
TARGET-20-PARZWH	Male	White	Hispanic or Latino	4243	Censored	2151	Alive	2151	2008	2014	AAML0531	29.5	92	97	No	No	M1	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	 	0	Normal	"46,XY[55]"	No	NA	No	No	Yes	No	Not done	Not done	Yes	10	No	0	CR	CR	Low Risk	Yes	Not Done	Not Done	Not Done	Not Done	Not Done	NA	NO Gentuzumab ozogamicin treatment		"Discovery,Validation,TMA"
TARGET-20-PASBBE	Male	White	Not Hispanic or Latino	3889	Relapse	342	Alive	2244	2008	2014	AAML0531	439.2	72	67	No	No	M4	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	del 7p	1	Other	"46,XY,del(7)(p11.2p15)[6]/46,XY[64]"	Yes	0.34	No	No	Yes	No	Not done	Not done	No	0	No	0	CR	CR	Low Risk	No	Yes	Yes	No	No	No	NA	NO Gentuzumab ozogamicin treatment		"Discovery,Validation,TMA"
TARGET-20-PASBHI	Male	White	Not Hispanic or Latino	2201	Censored	2342	Alive	2342	2008	2014	AAML0531	49.5	92	80	No	No	M1	No	Yes	No	No	No	No	No	No	No	No	Yes	No	No	No	No	No	No	No	del(9)(q13q22)	2	t(8;21)	"46,XY,t(8;21)(q22;q22),del(9)(q13q22)[20] "	No	NA	No	No	No	No	No	No	No	0	No	0	CR	CR	Low Risk	No	Not Done	Not Done	Not Done	Not Done	Not Done	RUNX1-RUNX1T1	Gentuzumab ozogamicin treatment		"Discovery,Validation"
TARGET-20-PASBPK	Male	Black or African American	Not Hispanic or Latino	161	Relapse	239	Alive	2117	2008	2014	AAML0531	162.9	90	70.6	No	Yes	M5	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	19	1	Other	"47,XY,+19[23]   "	No	NA	No	No	No	No	Not done	Not done	No	0			not in CR	CR	Standard Risk	No	Yes	Yes	Yes	No	Yes	NA	Gentuzumab ozogamicin treatment		"Discovery,Validation"
TARGET-20-PASCCS	Male	White	Not Hispanic or Latino	4357	Relapse	763	Alive	2221	2008	2014	AAML0531	6.6	90	76	No	No	M1	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	 	0	Normal	"46,XY[40] "	No	NA	No	Yes	No	No	Not done	Not done	Yes	2.2	No	0	CR	CR	Low Risk	No	Yes	No	No	No	No	NA	NO Gentuzumab ozogamicin treatment		"Discovery,Validation,TMA"
TARGET-20-PASCFW	Female	Asian	Not Hispanic or Latino	733	Censored	2205	Alive	2205	2008	2014	AAML0531	19.1	53	34	No	No	M7	No	No	No	No	No	No	No	No	No	No	No	No	No	Yes	No	No	No	No	"+7,+10,der(17)(q21;p13),+19"	5	Other	"50,XX,+7,+8,+10,der(17)t(2;17)(q21;p13),+19[14]/46,XX[11] "	No	NA	No		Unknown	Unknown	Not done	Not done	No	0	No	0	CR	CR	Standard Risk	No	Not Done	Not Done	Not Done	Not Done	Not Done	NA	NO Gentuzumab ozogamicin treatment		"Discovery,Validation,TMA"
TARGET-20-PASCGR	Female	White	Hispanic or Latino	6660	Relapse	255	Dead	702	2008	2010	AAML0531	5.2	31	0	No	Yes	M5	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	"del(10p),add(12p),t(11q;12q)"	4	MLL	"46,XX,del(10)(p13),der(11)t(11;12)(q13;q24.1),der(12)t(11;12)(q13;q24.1)inv(11)(q23q13)/46,idem,add(12)(p11.2) "	No	NA	No	No	No	No	Not done	Not done	No	0	No	0	not in CR	CR	Standard Risk	No	Yes	Yes	No	No	No	KMT2A-MLLT10	Gentuzumab ozogamicin treatment		"Discovery,Validation,TMA"
TARGET-20-PASCRZ	Male	White	Not Hispanic or Latino	5356	Relapse	241	Dead	339	2008	2009	AAML0531	203.3		96	No	No	M4	No	No	No	No	No	No	No	No	No	No	No	No	No	Yes	No	No	No	No	21q22 rearrangement	More than 6	Other	"47,XY,+10,t(16;21)(p11.2;q22)[2]/50,idem,+8,+12,+22[3]/47,idem,der(2)t(1;2)( q21;q31)[6]/48,idem,t(2;15)(q11.2;q11.2),+22[7]/44-47,idem,add(17)(q25)[2]"	No	NA	No	No	No	No	No	No	No	0.08			CR	CR	Standard Risk	No	Yes	Yes	No	No	No	NA	Gentuzumab ozogamicin treatment		"Discovery,Validation"
TARGET-20-PASFEW	Female	White	Unknown	428	Relapse	216	Dead	313	2008	2009	AAML0531	18.6	89	7	No	No	M7	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	 	1	Other	"46,XX,add(22)(q13.3)[18]/46,XX[2]"	No	NA	No	No	No	No	Not done	Not done	Yes	0.1	Yes	0.8	CR	CR	Standard Risk	No	Yes	No	No	Yes	No	CBFA2T3-GLIS2	NO Gentuzumab ozogamicin treatment		"Discovery,Validation"
TARGET-20-PASFLM	Male	White	Not Hispanic or Latino	5140	Relapse	771	Alive	2034	2008	2014	AAML0531	0.9	40.6	16	No	No	Not classified	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	 	0	Normal	"46,XY[59]"	Yes	0.81	No	No	No	No	Not done	Not done	No	0			CR	CR	High Risk	No	Yes	No	No	No	No	NA	NO Gentuzumab ozogamicin treatment		"Discovery,Validation,TMA"
TARGET-20-PASGMZ	Female	White	Not Hispanic or Latino	5129	Relapse	267	Dead	789	2008	2010	AAML0531	1.5	64	44	No	No	M1	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	 	0	Normal	"46,XX[20]"	No	NA	No	No	No	No	Not done	Not done	No	0	No	0	CR	CR	Standard Risk	No	Yes	No	No	No	No	NA	Gentuzumab ozogamicin treatment		"Discovery,Validation"
TARGET-20-PASGWH	Male	White	Not Hispanic or Latino	5251	Relapse	409	Dead	1214	2008	2012	AAML0531	14.2	35.4	61	No	No	M2	No	No	No	No	No	No	No	No	No	No	Yes	No	No	No	No	No	No	No	deletion 9q	1	Other	"46,XY,del(9)(q13q22)[16]/46,XY[4]"	No	NA	No	No	No	No	Not done	Not done	No	0	No	0.02	CR	CR	Standard Risk	No	Yes	No	No	No	Yes	NUP98-NSD1	NO Gentuzumab ozogamicin treatment		"Discovery,Validation,TMA"
TARGET-20-PASGZS	Female	White	Not Hispanic or Latino	446	Relapse	213	Dead	278	2008	2009	AAML0531	263.1	82	76.3	No	No	M4	No	No	No	Yes	No	No	No	No	No	No	No	No	No	No	No	Yes	No	No	 	1	MLL	"46,XX,t(6;11)(q27;q23)[24] "	No	NA	No	No	No	No	Not done	Not done	Yes	1	No	0	CR	CR	Standard Risk	Yes	Yes	No	No	No	No	KMT2A-MLLT4	Gentuzumab ozogamicin treatment		Discovery
TARGET-20-PASHBI	Male	White	Not Hispanic or Latino	5727	Censored	1335	Alive	1335	2008	2012	AAML0531	5.6	78	65	No	No	M2	No	Yes	No	No	No	No	No	No	No	No	No	No	No	No	No	No	Yes	No	#NAME?	2	t(8;21)	"45,X,-Y,t(8;21)(q22;q22)[19] "	No	NA	No	No	No	Yes	No	No	No	0	No	0	CR	CR	Low Risk	No	Not Done	Not Done	Not Done	Not Done	Not Done	RUNX1-RUNX1T1	Gentuzumab ozogamicin treatment		"Discovery,Validation"
TARGET-20-PASHYZ	Female	White	Not Hispanic or Latino	1695	Relapse	300	Dead	433	2008	2010	AAML0531	30.3	37.8	66	No	No	M2	No	Yes	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	Yes	#NAME?	2	t(8;21)	"45,X,-X,t(8;21)(q22;q22)[20]"	No	NA	No	No	No	No	No	Yes	No	0.03	No	0	CR	CR	Low Risk	No	Yes	No	No	No	No	RUNX1-RUNX1T1	NO Gentuzumab ozogamicin treatment		"Discovery,Validation,TMA"
TARGET-20-PASIBG	Male	White	Hispanic or Latino	748	Relapse	287	Dead	1094	2008	2011	AAML0531	55.3	73.2	85	No	No	M4	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	"t(7;12)(q36;p13),+19"	2	Other	"47,XY,t(7;12)(q36;p13),+19[20]"	No	NA	No	No	No	No	Not done	Not done	Yes	3.6	No	0	CR	CR	Standard Risk	Yes	Yes	No	No	No	No	MNX1-ETV6	NO Gentuzumab ozogamicin treatment		Discovery
TARGET-20-PASIEJ	Female	Asian	Not Hispanic or Latino	2686	Relapse	419	Dead	1118	2008	2011	AAML0531	5.4	30	19.1	No	No	M2	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	 	0	Normal	"46,XX[20]"	Yes	0.54	No	No	No	No	Not done	Not done	Yes	2.7	Yes	0.9	CR	CR	High Risk	No	Yes	No	No	No	No	CBFA2T3-GLIS2	Gentuzumab ozogamicin treatment		"Discovery,Validation,TMA"
TARGET-20-PASINN	Male	American Indian or Alaska Native	Not Hispanic or Latino	1330	Relapse	314	Dead	843	2008	2011	AAML0531	23.8	51	26	No	No	M2	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	t(16;21)(p11.2;q22)	1	Other	"46,XY,t(16;21)(p11.2;q22)[20]"	No	NA	No	Yes	No	Yes	Not done	Not done	No	0.02	No	0.02	CR	CR	Low Risk	No	Yes	No	No	No	No	FUS-ERG	NO Gentuzumab ozogamicin treatment		"Discovery,Validation"
TARGET-20-PASJGZ	Female	White	Not Hispanic or Latino	658	Relapse	277	Dead	462	2008	2010	AAML0531	11.5	50	6	No	No	M0 Undifferentiated	No	No	No	No	No	No	No	No	No	No	No	No	No	Yes	No	No	No	No	8	4	Other	"46,XX,del(3)(q21q26),del(13)(q12q14)[14]/48,idem,+6,+8[2]/46,XX[4] "	No	NA	No	No	No	No	Not done	Not done	No	0	No	0	CR	CR	Standard Risk	No	Yes	No	No	No	No	NUP98-KDM5A	Gentuzumab ozogamicin treatment		Discovery
TARGET-20-PASJTM	Male	Other	Not Hispanic or Latino	901	Censored	1953	Alive	1953	2008	2014	AAML0531	18.2	39	52	No	No	M7	No	No	No	No	No	No	No	No	Yes	No	No	No	No	No	No	No	No	No	"t(3;21)(q25;q22.3),r(7)(::p22->q36::?p15->?p22::),der(11)(11pter->11q13::11q24->11q22::7p15->7pter)"	4	Other	"46,XY,t(3;21)(q25;q22.3),del(5)(q31),r(7)(::p22->q36::?p15->?p22::),der(11)(11pter->11q13::11q24->11q22::7p15->7pter) "	No	NA	No	No	No	No	Not done	Not done	No	0	No	0	CR	CR	High Risk	Yes	Not Done	Not Done	Not Done	Not Done	Not Done	NA	NO Gentuzumab ozogamicin treatment		"Discovery,Validation"
TARGET-20-PASMGW	Male	White	Not Hispanic or Latino	3089	Relapse	237	Dead	286	2009	2009	AAML0531	23.5	85	51	No	No	M5	No	No	No	No	No	Yes	No	No	No	No	No	No	No	No	No	Yes	No	No	 	1	MLL	"46,XY,t(10;11)(p12;q23)[25]"	No	NA	No	No	No	No	Not done	Not done	No	0	No	0	not in CR	CR	Standard Risk	No	No	No	No	No	Yes	KMT2A-MLLT10	NO Gentuzumab ozogamicin treatment		"Discovery,Validation"
TARGET-20-PASMYS	Female	White	Hispanic or Latino	768	Relapse	341	Alive	1888	2009	2014	AAML0531	86.8	47.3	50	No	No	M4	No	No	No	No	No	No	No	No	No	No	No	No	No	Yes	No	No	No	No	 	1	Other	"47,XX,+8[19]/46,XX[1]"	No	NA	No	Yes	No	Yes	Yes	No	No	0	No	0	CR	CR	Low Risk	No	Yes	Yes	No	Yes	No	NA	Gentuzumab ozogamicin treatment		"Discovery,Validation,TMA"
TARGET-20-PASPGA	Female	White	Not Hispanic or Latino	1189	Relapse	1093	Dead	1729	2009	2013	AAML0531	35.8	96	95	No	No	M1	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	 	0	Normal	"46,XX[20]"	No	NA	No	Yes	No	No	Not done	Not done	Yes	1.2	No	0	CR	CR	Low Risk	No	Yes	No	No	No	No	NA	Gentuzumab ozogamicin treatment		"Discovery,Validation"
TARGET-20-PASPKE	Female	Black or African American	Not Hispanic or Latino	3200	Censored	2026	Alive	2026	2009	2014	AAML0531	11.9	73	58	Yes	No	M4	No	Yes	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	 	1	t(8;21)	"46,XX,t(5;21;8)(q31;q22;q22)[20] "	No	NA	No	No	No	No	Yes	No			No	0	CR	CR	Low Risk	No	Not Done	Not Done	Not Done	Not Done	Not Done	RUNX1-RUNX1T1	Gentuzumab ozogamicin treatment		"Discovery,Validation"
TARGET-20-PASPLU	Male	White	Not Hispanic or Latino	3399	Induction Failure	86	Dead	351	2009	2010	AAML0531	446	92.6	93	Yes	No	M4	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	 	0	Normal	"46,XY[20]"	Yes	0.52	No	No	No	Yes	Not done	Not done	No	0	Yes	57	CR	not in CR	High Risk	No	Yes	No	No	Yes	No	NUP98-NSD1	Gentuzumab ozogamicin treatment		"Discovery,Validation,TMA"
TARGET-20-PASPTM	Female	Asian	Not Hispanic or Latino	5122	Censored	1900	Alive	1900	2009	2014	AAML0531	60.6	70	77	No	No	M2	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	 	0	Normal	"46,XX[20]"	No	NA	No	No	Yes	No	Not done	Not done			No	0	CR	CR	Low Risk	No	Not Done	Not Done	Not Done	Not Done	Not Done	NA	Gentuzumab ozogamicin treatment		"Discovery,Validation,TMA"
TARGET-20-PASSSI	Male	Native Hawaiian or other Pacific Islander	Hispanic or Latino	530	Relapse	462	Dead	712	2009	2011	AAML0531	198.8	91	78	No	Yes	M5	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	 	1	MLL	"46,XY,cryp ins(10;11)(p12;q23q23)  "	No	NA	No	No	No	No	Not done	Not done	No	0	No	0	CR	CR	Standard Risk	No	Yes	Yes	No	No	No	KMT2A-MLLT10	Gentuzumab ozogamicin treatment		"Discovery,Validation,TMA"
TARGET-20-PASTTW	Female	Unknown	Not Hispanic or Latino	757	Relapse	475	Dead	600	2009	2011	AAML0531	31.1	93	0	No	No	M7	No	No	No	No	No	No	No	No	No	No	No	No	No	No	Yes	No	No	No	21	1	Other	"46,XX,+21[15]/46,XX[5] "	No	NA	No	No	No	No	Not done	Not done	Yes	0.1	Yes	0.1	CR	unevaluable	Standard Risk	No	Yes	No	No	No	No	CBFA2T3-GLIS2	NO Gentuzumab ozogamicin treatment		Discovery
TARGET-20-PASTUH	Female	White	Not Hispanic or Latino	5305	Relapse	118	Dead	166	2009	2009	AAML0531	33.5	81.6	46	No	No	M4	No	No	No	No	No	No	Yes	No	No	No	No	No	No	Yes	No	Yes	No	Yes	 	3	MLL	"46,XX,t(11;19)(q23;p13.1)[15]/46,idem,-X,+8[3]/46,XX[2]"	No	NA	No	No	No	No	Not done	Not done	Yes	2.1	Yes	1	CR	CR	Standard Risk	No	Yes	No	No	No	No	KMT2A-ELL	Gentuzumab ozogamicin treatment		"Discovery,Validation"
TARGET-20-PASVVS	Male	White	Not Hispanic or Latino	283	Relapse	519	Alive	1968	2009	2014	AAML0531	169	88	55	No	No	M5	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	ins(11q23 into 20p)	4	MLL	"46,Y,der(X)t(X;11)(q24;q23),der(11)(11pter->11q21::11q23->11q23::Xq24->Xqter),inv(12)(p13q13),ins(20;11)(p11.2;q23q21)[16]/47,idem,+2[3]/46,XY[1] "	No	NA	No	No	No	No	Not done	Not done	No	0	Yes	14	not in CR	CR	Standard Risk	No	No	No	No	Yes	No	KMT2A-SEPT6	Gentuzumab ozogamicin treatment		"Discovery,Validation,TMA"
TARGET-20-PASVYA	Male	White	Hispanic or Latino	590	Relapse	291	Dead	630	2009	2011	AAML0531	16.4	49	0	No	No	M7	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	 	0	Normal	"46,XY[20] "	No	NA	No	No	No	No	Not done	Not done	No	0.02	No	0.03	CR	CR	Standard Risk	No	Yes	No	No	Yes	No	CBFA2T3-GLIS2	Gentuzumab ozogamicin treatment		"Discovery,Validation,TMA"
TARGET-20-PASVYL	Male	White	Not Hispanic or Latino	6090	Relapse	206	Dead	286	2009	2010	AAML0531	43	80	90	No	No	M5	No	No	No	No	No	No	Yes	No	No	No	No	No	No	No	No	Yes	No	No	 	1	MLL	"46,XY,t(11;19)(q23;p13.3)[20] "	No	NA	No	No	No	No	Not done	Not done	No	0	No	0	CR	CR	Standard Risk	No	No	Yes	Yes	No	No	KMT2A-MLLT1	NO Gentuzumab ozogamicin treatment		"Discovery,Validation,TMA"
TARGET-20-PASWAJ	Female	White	Not Hispanic or Latino	3298	Relapse	422	Alive	1712	2009	2014	AAML0531	86.6	95	89	No	No	M1	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	 	1	MLL	"46,XX,cryp ins(11;6)(q23;q27q27)  "	No	NA	No	No	No	No	Not done	Not done	No	0			CR	CR	Standard Risk	No	Yes	No	No	No	No	KMT2A-MLLT4	NO Gentuzumab ozogamicin treatment		"Discovery,Validation,TMA"
TARGET-20-PASWAT	Female	White	Not Hispanic or Latino	5157	Relapse	286	Dead	342	2009	2010	AAML0531	49.5	54	40	No	No	M4	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	 	0	Normal	"46,XX[30]"	No	NA	No	No	No	No	Not done	Not done	Yes	5.3	Yes	2.2	CR	CR	Standard Risk	No	Yes	No	No	No	No	KMT2A-SEPT6	Gentuzumab ozogamicin treatment		"Discovery,Validation"
TARGET-20-PASWLN	Female	White	Not Hispanic or Latino	6631	Relapse	513	Dead	614	2009	2011	AAML0531	32.4	96	86	No	No	M0 Undifferentiated	No	No	No	No	Yes	No	No	No	No	No	No	No	No	No	No	Yes	No	No	 	1	MLL	"46,XX,t(9;11)(p22;q23)[20]"	No	NA	No	No	No	No	Not done	Not done	Yes	15	No	0	not in CR	CR	Standard Risk	No	Yes	No	No	No	Yes	KMT2A-MLLT3	NO Gentuzumab ozogamicin treatment		"Discovery,Validation,TMA"
TARGET-20-PASWPD	Male	Other	Hispanic or Latino	1454	Relapse	357	Dead	689	2009	2011	AAML0531	2		4	No	No	Not classified	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	 	NA	Unknown	Unknown	No	NA	No	No	No	No	Not done	Not done	No	0			CR	CR	Unknown	No	Yes	No	No	No	No	NA	Gentuzumab ozogamicin treatment		"Discovery,Validation"
TARGET-20-PASWPT	Male	Other	Hispanic or Latino	3438	Relapse	395	Dead	518	2009	2010	AAML0531	44.2	72	74	No	No	M2	No	Yes	No	No	No	No	No	No	No	No	No	No	No	No	No	No	Yes	No	 	3	t(8;21)	"45,X,-Y,t(8;21)(q22;q22)[9}/46,idem,+4[11]"	No	NA	No	No	No	No	No	Yes			No	0	CR	CR	Low Risk	No	No	Yes	Yes	No	No	RUNX1-RUNX1T1	NO Gentuzumab ozogamicin treatment		"Discovery,Validation,TMA"
TARGET-20-PASXNR	Female	White	Not Hispanic or Latino	890	Relapse	255	Dead	542	2009	2011	AAML0531	165.4	71.5	85	No	No	M4	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	"-16,der(21)t(16;21)(p11.2;q22),t(3;7)(p21;q32)"	3	Other	"45,XX,-16,der(21)t(16;21)(p11.2;q22)[28]/45,idem,t(3;7)(p21;q32)[4] "	No	NA	No	No	No	No	Not done	Not done	No	0.07	No	0.07	CR	CR	Standard Risk	No	Yes	No	No	No	No	FUS-ERG	Gentuzumab ozogamicin treatment		"Discovery,Validation,TMA"
TARGET-20-PASXYG	Female	White	Hispanic or Latino	4103	Relapse	250	Dead	570	2009	2011	AAML0531	40.5	63.5	68	No	Yes	M2	No	Yes	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	Yes	#NAME?	2	t(8;21)	"46,XX,t(8;21)(q22;q22)[5]/45,idem,-X[15]"	No	NA	Yes	No	No	No	No	No	No	0	No	0	not in CR	CR	Low Risk	No	Yes	No	No	Yes	No	RUNX1-RUNX1T1	Gentuzumab ozogamicin treatment		"Discovery,Validation,TMA"
TARGET-20-PASYJI	Female	White	Not Hispanic or Latino	4545	Relapse	289	Alive	1780	2009	2014	AAML0531	31.1	63	56	No	No	M4	No	No	No	No	No	No	No	Yes	No	No	No	No	No	No	No	No	No	No	 	1	inv(16)	"46,XX,inv(16)(p13.1q22)[18]/46,XX[2]"	No	NA	No	No	No	No	Yes	No	No	0	No	0	CR	CR	Low Risk	No	Yes	No	No	Yes	No	CBFB-MYH11	NO Gentuzumab ozogamicin treatment		"Discovery,Validation,TMA"
TARGET-20-PASZLJ	Female	White	Not Hispanic or Latino	3543	Relapse	127	Dead	289	2009	2010	AAML0531	24.2	95	77	No	No	M5	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	"add(2)(q37),-10,dup(7)(p15p22)"	6	MLL	"45,XX,add(2)(q37),-10,der(11)del(11)(q13q22)trp(11)(q23q23) t(10;11)(q11.2;q23)[14]/45,idem,-der(2),dup(7)(p15p22)[4]/46,XX[2]  "	No	NA	No	No	No	No	Not done	Not done	Yes	0.1	No	0.05	CR	CR	Standard Risk	No	No	No	No	Yes	No	KMT2A-MLLT10	Gentuzumab ozogamicin treatment		"Discovery,Validation,TMA"
TARGET-20-PATDHA	Female	White	Hispanic or Latino	5544	Relapse	194	Dead	403	2009	2011	AAML0531	1.6	86	21	Yes	No	M2	No	Yes	No	No	No	No	No	No	No	No	Yes	No	No	No	No	No	No	No	del(9)(q12q22)	2	t(8;21)	"46,XX,t(8;21)(q22;q22)[18]/46,idem,del(9)(q12q22)[2] "	No	NA	No	No	No	No	No	No	No	0	No	0	not in CR	CR	Low Risk	No	Yes	No	No	No	No	RUNX1-RUNX1T1	Gentuzumab ozogamicin treatment		"Discovery,Validation,TMA"
TARGET-20-PATDNN	Male	White	Hispanic or Latino	1262	Relapse	102	Dead	194	2009	2010	AAML0531	210.9	89	94	No	No	M5	No	No	No	No	Yes	No	No	No	No	No	No	No	No	No	No	Yes	No	No	 	3	MLL	"46,XY,t(9;11)(p22;q23)[8}/48,idem,+2mar[12]"	No	NA	No	No	No	No	Not done	Not done	No	0	No	0	CR	CR	Standard Risk	No	Yes	No	No	No	No	KMT2A-MLLT3	NO Gentuzumab ozogamicin treatment		"Discovery,Validation,TMA"
TARGET-20-PATIAK	Female	Black or African American	Not Hispanic or Latino	227	Relapse	277	Alive	1464	2010	2014	AAML0531	45.8	62	59	No	No	M4	No	No	No	No	No	No	No	Yes	No	No	No	No	No	No	No	No	No	No	 	1	inv(16)	"46,XX,inv(16)(p13.1q22)[17]/46,XX[3]"	No	NA	Yes	No	No	No	Yes	No	No	0	No	0	CR	CR	Low Risk	No	Yes	No	No	No	No	CBFB-MYH11	NO Gentuzumab ozogamicin treatment		"Discovery,Validation,TMA"
TARGET-20-PATJHJ	Female	Black or African American	Not Hispanic or Latino	137	Relapse	252	Dead	607	2010	2011	AAML0531	519		90	No	No	M5	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	 	1	MLL	"46,XX,t(4;11)(q21;q23)[14]/46,XX[6]"	No	NA	No	No	No	No	Not done	Not done	No	0	No	0	CR	CR	Standard Risk	No	Yes	Yes	No	Yes	No	KMT2A-AFF1	NO Gentuzumab ozogamicin treatment		"Discovery,Validation"
TARGET-21-PARLSL	Male	White	Not Hispanic or Latino	4456	Censored	1077	Alive	1077	2007	2010	AAML0531	28.6	87	0	No	No	Unknown	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	 	0	Normal	"46,XY[20]"	No	NA	No	Yes	No	No	Not done	Not done	Yes	15	No	0	not in CR	CR	Low Risk	Yes	Not Done	Not Done	Not Done	Not Done	Not Done	NA	Gentuzumab ozogamicin treatment	EOI I	"This case is also found in the AML validation clinical data for frequency testing (TCS) - Induction Failure,Validation"
TARGET-21-PARXYR	Female	White	Not Hispanic or Latino	5346	Relapse	492	Alive	2200	2008	2014	AAML0531	38.7	21	80	No	No	M1	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	 	0	Normal	"46,XX[20] "	Yes	0.03	No	No	No	Yes	Not done	Not done	Yes	18	No	0	not in CR	CR	Standard Risk	Yes	Yes	No	No	No	No	NUP98-NSD1	NO Gentuzumab ozogamicin treatment	EOI I	Induction Failure
TARGET-21-PARZIA	Female	Asian	Not Hispanic or Latino	6089	Death without Remission	77	Dead	77	2008	2008	AAML0531	2.4	79		No	No	M0 Undifferentiated	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	 	1	Other	"47,XX,+10[7]/46,XX[13]"	No	NA	No	No	No	No	Not done	Not done	Yes	68	Yes	53	not in CR	death	Standard Risk	No	Not Done	Not Done	Not Done	Not Done	Not Done	NA	Gentuzumab ozogamicin treatment	EOI II	"This case is also found in the AML validation clinical data for frequency testing (TCS) - Induction Failure,Validation,TMA"
TARGET-21-PASDKZ	Female	Asian	Not Hispanic or Latino	1875	Death	188	Dead	188	2008	2009	AAML0531	53.5	73.2	47	No	No	M4	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	 	0	Normal	"46,XX[20] "	Yes	0.61	No	No	No	Yes	Not done	Not done	Yes	34			not in CR	not in CR	High Risk	Unknown	Not Done	Not Done	Not Done	Not Done	Not Done	NUP98-NSD1	Gentuzumab ozogamicin treatment	EOI I	Induction Failure
TARGET-21-PASFHK	Male	White	Hispanic or Latino	2164	Induction Failure	85	Alive	1655	2008	2013	AAML0531	340.7	93.8	83	No	No	M4	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	"9p loss, gain of 9q"	2	Other	"46,XY,add(14)(q32)[18]/45,idem,psu dic(9;9)(p11;p22)[2]"	No	NA	Yes	No	No	No	Not done	Not done	Yes	59	Yes	45	not in CR	not in CR	Standard Risk	Unknown	Yes	No	No	No	No	NA	NO Gentuzumab ozogamicin treatment	EOI I	"Induction Failure, TMA"
TARGET-21-PASFJJ	Female	White	Not Hispanic or Latino	3836	Censored	2205	Alive	2205	2008	2014	AAML0531	121.1	96	93	No	No	M1	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	 	0	Normal	"46,XX,inv(2)(p13q22)mat[25]  "	Yes	0.85	No	No	No	Yes	Not done	Not done	Yes	22	No	0	not in CR	CR	High Risk	Yes	Not Done	Not Done	Not Done	Not Done	Not Done	NA	Gentuzumab ozogamicin treatment	EOI I	"This case is also found in the AML validation clinical data for frequency testing (TCS) - Induction Failure,Validation,TMA"
TARGET-21-PASFLG	Male	White	Hispanic or Latino	3971	Induction Failure	69	Dead	694	2008	2010	AAML0531	414.8	95	89	No	No	M4	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	 	NA	Unknown	Unknown	Yes	1.43	No	No	No	Yes	Not done	Not done	Yes	14	Yes	26	not in CR	not in CR	High Risk	Unknown	Yes	No	No	No	No	NUP98-NSD1	NO Gentuzumab ozogamicin treatment	EOI I	"This case is also found in the AML validation clinical data for frequency testing (TCS) - Induction Failure,Validation,TMA"
TARGET-21-PASLZE	Female	Black or African American	Not Hispanic or Latino	3711	Induction Failure	84	Dead	707	2009	2011	AAML0531	28.1		75	No	No	Unknown	No	Yes	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	 	1	t(8;21)	"46,XX,t(8;21)(q22;q22)[20]"	No	NA	No	No	No	No	No	No	Yes	22	Yes	1.5	not in CR	not in CR	Low Risk	Unknown	Yes	No	No	No	No	RUNX1-RUNX1T1	NO Gentuzumab ozogamicin treatment	EOI I	"This case is also found in the AML validation clinical data for frequency testing (TCS) - Induction Failure,Validation"
TARGET-21-PASNKZ	Female	White	Not Hispanic or Latino	6491	Death	195	Dead	195	2009	2009	AAML0531	3.3	64.4	4	No	No	M1	No	No	No	No	No	No	No	No	No	Yes	No	No	No	No	No	No	No	No	 	1	Other	"46,XX,del(7)(q22)[15]/46,XX[5] "	No	NA	No	No	No	No	Not done	Not done	Yes	23	Yes	2.6	not in CR	CR	Standard Risk	No	Not Done	Not Done	Not Done	Not Done	Not Done	NA	Gentuzumab ozogamicin treatment	EOI I	Induction Failure
TARGET-21-PASSLT	Male	Unknown	Hispanic or Latino	5405	Induction Failure	36	Dead	87	2009	2009	AAML0531	114.7	96	94	No	No	M0 Undifferentiated	No	No	No	No	No	Yes	No	No	No	No	No	No	No	No	No	Yes	No	No	t(10;11)(p13;q14)	More than 6	MLL	"46,XY,t(10;11)(p13;q14),der(17)t(17;17)(p13;q21),del(12)(p12),+2 mar[4]/48,idem,t(13;15)(q32;q13)[11]/48,idem,add(3)(p12),der(4)inv(4)(q12q25)add(4)(q25),-del(12),der(13)(13pter->13q34::?3p21->3p13::4q25->4qter)[5]"	No	NA	No	No	No	No	Not done	Not done	Yes	61			not in CR	not in CR	Standard Risk	Unknown	No	Yes	No	No	No	MLLT10-PICALM	Gentuzumab ozogamicin treatment	EOI I	"Induction Failure, TMA"
TARGET-21-PASTZK	Male	Black or African American	Not Hispanic or Latino	2145	Induction Failure	58	Dead	102	2009	2009	AAML0531	17.9	55	45	No	No	M2	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	"t(X;10)(p11.2;p11.2),add(17)(p11.2)"	2	Other	"46,Y,t(X;10)(p11.2;p11.2),add(17)(p11.2)[13]/46,XY[6] "	No	NA	No	No	No	Yes	Not done	Not done	Yes	48	Yes	8.8	not in CR	not in CR	Standard Risk	Unknown	Yes	No	No	No	No	NA	NO Gentuzumab ozogamicin treatment	EOI I	"This case is also found in the AML validation clinical data for frequency testing (TCS) - Induction Failure,Validation,TMA"
TARGET-21-PASVJS	Female	White	Not Hispanic or Latino	1913	Induction Failure	71	Dead	1298	2009	2013	AAML0531	58.2	58	52	No	No	Unknown	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	 	0	Normal	"46,XX,[20]"	Yes	0.04	No	No	No	No	Not done	Not done			Yes	70	not in CR	not in CR	Standard Risk	Unknown	Yes	No	No	No	No	NA	NO Gentuzumab ozogamicin treatment	EOI II	Induction Failure
TARGET-21-PASYEJ	Female	White	Not Hispanic or Latino	889	Induction Failure	69	Dead	988	2009	2012	AAML0531	11.2	21	8	No	No	Not classified	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	 	0	Normal	"46,XX[30]"	No	NA	No	No	No	No	Not done	Not done	Yes	7.9	Yes	4.4	not in CR	not in CR	Standard Risk	Unknown	Yes	No	No	No	No	NA	Gentuzumab ozogamicin treatment	EOI I	"This case is also found in the AML validation clinical data for frequency testing (TCS) - Induction Failure,Validation,TMA"
TARGET-21-PASYWA	Male	White	Not Hispanic or Latino	5181	Induction Failure	79	Alive	295	2009	2010	AAML0531	19.1	95	68	No	No	M0 Undifferentiated	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	 	0	Normal	"46,XY[20]"	Yes	0.93	No	No	No	No	Not done	Not done	Yes	88	Yes	73	not in CR	not in CR	High Risk	Unknown	Yes	No	No	No	No	NA	Gentuzumab ozogamicin treatment	EOI I	"This case is also found in the AML validation clinical data for frequency testing (TCS) - Induction Failure,Validation,TMA"
TARGET-21-PATAIJ	Female	Black or African American	Not Hispanic or Latino	417	Induction Failure	57	Alive	1660	2009	2014	AAML0531	149.5	77.5	72	No	Yes	M5	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	inv(17)(p13.1q11.2)	2	MLL	"46,XX,cryp ins(10;11)(p12;q23q23),inv(17)(p13.1q11.2)[20]  "	No	NA	No	No	No	No	Not done	Not done	Yes	19			not in CR	not in CR	Standard Risk	Unknown	Yes	No	No	No	No	KMT2A-MLLT10	Gentuzumab ozogamicin treatment	EOI I	"This case is also found in the AML validation clinical data for frequency testing (TCS) - Induction Failure,Validation,TMA"
TARGET-21-PATHIU	Male	White	Not Hispanic or Latino	4859	Relapse	374	Dead	454	2010	2011	AAML0531	4.8	49	2	No	No	M5	No	No	No	No	No	No	No	No	No	No	No	No	No	Yes	No	No	No	No	 	1	Other	"47,XY,+8[14]/46,XX[6] "	No	NA	No	No	No	No	Not done	Not done	Yes	18	Yes	13	not in CR	CR	Standard Risk	Yes	No	No	No	No	Yes	NA	NO Gentuzumab ozogamicin treatment	EOI I	"Induction Failure, TMA"
TARGET-21-PATISD	Male	White	Not Hispanic or Latino	3901	Induction Failure	46	Dead	148	2010	2010	AAML0531	63.9	91	77	No	No	Not classified	No	No	No	No	No	No	No	No	No	No	No	No	Yes	No	No	No	No	No	 	2	Other	"45,XY,t(3;3)(q21;q26),-7[20]  "	No	NA	No	No	No	No	Not done	Not done	Yes	73	Yes	46	not in CR	not in CR	High Risk	Unknown	Yes	No	No	No	No	NA	NO Gentuzumab ozogamicin treatment	EOI I	"This case is also found in the AML validation clinical data for frequency testing (TCS) - Induction Failure,Validation,TMA"
TARGET-21-PATJMY	Male	White	Not Hispanic or Latino	1799	Induction Failure	77	Dead	319	2010	2011	AAML0531	6.5	40	60	No	No	M2	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	 	0	Normal	"46,XY[20]"	No	NA	No	No	No	Yes	Not done	Not done	Yes	31	Yes	15	not in CR	not in CR	Standard Risk	Unknown	Yes	No	No	No	No	NUP98-NSD1	Gentuzumab ozogamicin treatment	EOI I	"This case is also found in the AML validation clinical data for frequency testing (TCS) - Induction Failure,Validation,TMA"
TARGET-21-PATKBK	Male	White	Hispanic or Latino	31	Censored	1684	Alive	1684	2010	2014	AAML0531	27.6	30	23	No	No	M7	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	 	1	Other	"46,XY,t(1;22)(p13;q13)[7]/46,XY[13]"	No	NA	No	No	No	No	Not done	Not done	Yes	9.2	Yes	0.3	not in CR	CR	Standard Risk	No	Not Done	Not Done	Not Done	Not Done	Not Done	RBM15-MKL1	NO Gentuzumab ozogamicin treatment	EOI I	"This case is also found in the AML validation clinical data for frequency testing (TCS) - Induction Failure,Validation"
TARGET-21-PATKKJ	Female	Unknown	Not Hispanic or Latino	8581	Death	451	Dead	451	2010	2011	AAML0531	22.9	65	85	No	No	M2	No	No	No	No	No	No	No	No	No	No	No	No	No	No	Yes	No	No	No	21	2	Other	"46,XX,add(9)(p13),+21[16]/46,XX[2]"	No	NA	No	No	No	Yes	Not done	Not done	Yes	62			not in CR	not in CR	Standard Risk	Unknown	Not Done	Not Done	Not Done	Not Done	Not Done	NA	NO Gentuzumab ozogamicin treatment	EOI I	"This case is also found in the AML validation clinical data for frequency testing (TCS) - Induction Failure,Validation,TMA"
TARGET-21-PATKWH	Male	White	Not Hispanic or Latino	6008	Relapse	504	Dead	701	2010	2012	AAML0531	1.5	20	12	No	No	M6	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	 	0	Normal	"46,XY[20]"	Yes	0.05	No	No	No	Yes	Not done	Not done	Yes	8.6	Yes	6.1	CR	CR	Standard Risk	No	Yes	No	No	No	No	NA	NO Gentuzumab ozogamicin treatment	EOI II	"This case is also found in the AML validation clinical data for frequency testing (TCS) - Induction Failure,Validation"
TARGET-20-PABLDZ	Female	White	Not Hispanic or Latino	2455	Relapse	714	Alive	721	1997	1999	CCG2961	6	93	0	No	No	M4	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	 	0	Unknown	G	Yes	0.82	No	No	No	No	Not done	Not done					CR	CR	High Risk	No	Yes	No	No	No	No	NA			"Discovery,Validation"
TARGET-20-PADYIR	Male	White	Not Hispanic or Latino	1159	Relapse	373	Dead	585	1996	1998	CCG2961	13.1	29	11	No	No	M2	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	 	NA	Unknown	Unknown	No	NA	No	No	No	No	Not done	Not done					CR	CR	Unknown	Yes	Yes	No	No	No	No	NUP98-NSD1			"Discovery,Validation"
TARGET-20-PADZCG	Female	Unknown	Not Hispanic or Latino	5325	Relapse	314	Dead	536	1996	1998	CCG2961	29.3	58	5	No	No	M4	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	 	0	Normal	"46,XX[20]"	No	NA	No	No	No	No	Not done	Not done					not in CR	CR	Standard Risk	No	Yes	No	No	No	No	NA			"Discovery,Validation"
TARGET-20-PAEAKL	Female	Black or African American	Not Hispanic or Latino	5218	Relapse	134	Dead	163	1997	1997	CCG2961	96.1	80	81	Yes	No	M5	No	No	No	No	Yes	No	Yes	No	No	No	No	No	No	No	No	Yes	No	No	 	1	MLL	"46,XX,t(11:19)(q23:p13.1)[20]"	No	NA	No	No	No	No	Not done	Not done					CR	CR	Standard Risk	No	No	No	No	No	Yes	KMT2A-ELL			"Discovery,Validation"
TARGET-20-PAECCE	Male	White	Not Hispanic or Latino	900	Induction Failure	85	Dead	147	1997	1997	CCG2961	98.3	95	0	No	No	M5	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	 	NA	Unknown	Unknown	No	NA	No	No	No	No	Not done	Not done					CR	not in CR	Unknown	No	Yes	No	Yes	No	No	KMT2A-MLLT10			"Discovery,Validation"
TARGET-20-PAEDKB	Male	White	Not Hispanic or Latino	815	Relapse	419	Dead	800	1997	1999	CCG2961	5.2	60	0	No	No	M4	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	 	0	Normal	"46,XY[20]"	No	NA	No	No	Unknown	No	Not done	Not done					CR	CR	Standard Risk	No	Yes	No	No	No	No	NA			"Discovery,Validation"
TARGET-20-PAEERJ	Female	White	Not Hispanic or Latino	5082	Relapse	259	Dead	373	1997	1998	CCG2961	71.9	60	41	No	No	M4	No	No	Yes	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	 	1	Other	"46,XX,t(3:5)(q23:q33)[19]/46,XX[1]"	Yes	0.55	No	No	No	Yes	Not done	Not done					CR	CR	High Risk	No	Yes	No	No	No	No	NPM1-MLF1			"Discovery,Validation"
TARGET-20-PAEFGR	Female	White	Not Hispanic or Latino	549	Relapse	497	Alive	4022	1997	2008	CCG2961	51.2	75	41	No	No	M2	No	No	No	No	No	No	No	Yes	No	No	No	No	No	No	No	No	No	No	 	1	inv(16)	"46,XX,inv(16)(p13q22)[21]/46,XX[1]"	No	NA	No	No	No	No	Yes	No					CR	CR	Low Risk	No	Yes	Yes	No	No	No	CBFB-MYH11			"Discovery,Validation"
TARGET-20-PAEFGT	Female	White	Not Hispanic or Latino	5452	Relapse	213	Dead	315	1997	1998	CCG2961	11.4	100	70	No	No	M2	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	 	0	Unknown	I	Yes	0.83	No		No	Yes	Not done	Not done					CR	CR	High Risk	No	Yes	No	No	No	No	NA			"Discovery,Validation"
TARGET-20-PAEIKD	Male	Black or African American	Not Hispanic or Latino	282	Relapse	809	Alive	3600	1998	2008	CCG2961	13.2	87	0	No	No	M5	No	No	No	No	Yes	No	No	No	No	No	No	No	No	No	No	Yes	No	No	 	1	MLL	"46,XY,t(9:11)(p22:q23)[19]/46,XY[1]"	No	NA	Yes	No	No	No	Not done	Not done					CR	CR	Standard Risk	No	Yes	No	No	No	No	KMT2A-MLLT3			"Discovery,Validation"
TARGET-20-PAKERZ	Female	White	Not Hispanic or Latino	1022	Relapse	221	Dead	397	2000	2001	CCG2961	4.8	89	32	No	No	M1	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown	 	0	Unknown	I	No	NA	No	No	No	No	Not done	Not done					unevaluable	CR	Unknown	No	Yes	No	No	No	No	NUP98-KDM5A			"Discovery,Validation"
TARGET-20-PAKIWK	Male	White	Not Hispanic or Latino	1248	Relapse	107	Alive	112	2000	2001	CCG2961	13.9	14	3	No	No	M6	No	No	No	No	No	No	No	No	No	No	Yes	No	No	No	No	No	No	No	 	2	Other	"46,XY,del(9)(q22q34)[13]/46,idem,add(18)(p13)[4]/46,XY[3]"	No	NA	No		No	Unknown	Not done	Not done					CR	CR	Standard Risk	No	Yes	No	No	No	No	NA			"Discovery,Validation"
TARGET-20-PAKIYW	Female	White	Not Hispanic or Latino	163	Relapse	461	Alive	2965	2000	2008	CCG2961	136	73	68	No	No	M4	No	No	No	No	Yes	No	No	No	No	No	No	No	No	No	No	Yes	No	No	 	1	MLL	"46,XX,t(9:11)(p22:q23)[15]/46,XX[3]"	No	NA	No		No	Unknown	Not done	Not done					CR	CR	Standard Risk	No	Yes	No	No	No	No	KMT2A-MLLT3			Discovery
TARGET-20-PAKLPD	Female	White	Not Hispanic or Latino	147	Censored	2707	Alive	2707	2000	2008	CCG2961	194.4	75	84	Yes	No	M5	No	No	No	No	Yes	No	Yes	No	No	No	No	No	No	No	No	Yes	No	No	 	1	MLL	"46,XX,t(11:19)(q23:p13)[20]"	No	NA	No	No	No	No	Not done	Not done					CR	CR	Standard Risk	Yes	Not Done	Not Done	Not Done	Not Done	Not Done	KMT2A-ELL			"Discovery,Validation"
TARGET-20-PAKTCX	Female	White	Not Hispanic or Latino	3262	Relapse	269	Dead	1896	2001	2006	CCG2961	3.9	40	2	No	No	M4	No	No	No	No	Yes	No	Yes	No	No	No	No	No	No	No	No	Yes	No	No	 	1	MLL	"46,XX,t(11:19)(q23:p13.1)"	No	NA	No		No	Unknown	Not done	Not done					CR	CR	Standard Risk	No	Yes	No	No	No	No	KMT2A-ELL			"Discovery,Validation"
TARGET-20-PAKVGI	Female	White	Not Hispanic or Latino	645	Relapse	665	Dead	1229	2001	2004	CCG2961	11.3	30	6	No	No	M7	No	No	No	No	No	No	No	No	No	No	No	No	No	No	Yes	No	No	No	 	5	Other	"46,XX,t(7:10:16)(p15:q23:p11.2),del(13)(q12q21)[10]/49,idem,+X,+6,+21[8]/46,XX[10]"	No	NA	No	No	No	No	Not done	Not done					CR	CR	Standard Risk	No	Yes	No	No	No	No	NUP98-KDM5A			"Discovery,Validation"
TARGET-20-PALGKX	Female	Unknown	Hispanic or Latino	4723	Relapse	214	Dead	485	2001	2003	CCG2961	69.2	73	83	No	No	M2	No	Yes	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	 	3	t(8;21)	"46,XX,der(7)t(7:9)(q22:q13),t(8:21)(q22:q22),add(9)(q13)[20]"	No	NA	No	No	No	No	No	Yes					CR	CR	Low Risk	No	Yes	No	No	No	No	RUNX1-RUNX1T1			"Discovery,Validation"